AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

HSCS · NASDAQ · Medical - Devices

HeartSciences

Operates a device-agnostic ECG workflow and AI-algorithm marketplace.

$3.12

After-hours close+0.09 (+2.97%)

At close$3.03(−2.88%)

Something off on this page? Send us feedback.

Profile

HeartSciences Inc.HSCSHealth Care

Sells ECG workflow software and plans subscription and algorithm-access revenue while developing its own AI-enabled resting ECG system. Its device-agnostic platform works with hospitals’ installed ECG equipment, but clinical algorithms and proprietary hardware depend on applicable regulatory authorization.

Operates MyoVista Insights, a cloud-native platform that collects electrocardiograms from existing machines, manages workflows, and distributes compatible AI algorithms through a marketplace. Revenue is intended to come from implementation fees, subscription usage, and algorithm access; device sales, electrodes, and software support the separate MyoVista wavECG model. The United States is the planned direct-sales market, with distributors intended for markets outside it.

Combines internally developed technology with licenses from Mount Sinai and the University of Glasgow. MyoVista wavECG and the company's clinical algorithms remain subject to FDA authorization for U.S. marketing, while the platform's data-system exemption does not automatically apply to hosted algorithms. The old European CE mark for MyoVista lapsed, limiting proprietary-hardware access there.

Company facts

CEOAndrew Simpson

ListedJun 15, 2022

ExchangeNASDAQ

HeadquartersSouthlake, TX

CountryUnited States

Employees15

CIK0001468492

ISINUS42254E3027

Key statistics

Market cap$6.5M

EPS (ttm)−$3.92

P/E (ttm)−0.7730

ROE-358.4%

P/B42.39

P/S1,515.00

Dividend yield—

Beta0.05vs XLV 1.06

Year to date −3.5% · Average volume (30d) 98.7K

Analysts

Price target, next 12 months$3.00−1.0%Median of 3 analysts · vs the Aug 28 close

ConsensusBuy3 of 3 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $3.03

High$3.00−1.0%

Median$3.00−1.0%

Low$3.00−1.0%

12 months agoNowIn 12 months

Latest analyst notes

No analyst notes in the last 24 months.

Earnings

EPS

Estimate−$0.72

ReportedDue Sep 10, 2026

Revenue

Estimate$100.0K

ReportedDue Sep 10, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 23, 2026	−$0.66	−$0.88	−33.3%	$50.0K	—	—	−2.05%
Mar 16, 2026Q3 FY26	−$0.84	−$0.63	+25.0%	$200.0K	—	—	−0.38%
Dec 15, 2025Q2 FY26	−$0.90	−$0.85	+5.6%	—	$2.4K	—	−6.48%
Sep 11, 2025Q1 FY26	−$2.41	−$1.58	+34.4%	—	$1.9K	—	−9.88%

View details

Financial highlights

	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q4 FY26	Q3 FY26
Revenue	$0	$4.4K	$1.9K	$2.4K	$0	$0
Gross profit	−$29.0K	−$28.8K	−$30.5K	−$31.0K	−$34.0K	−$33.2K
Operating income	−$2.4M	−$1.9M	−$1.9M	−$2.1M	−$2.5M	−$1.9M
Net income	−$2.5M	−$2.1M	−$2.1M	−$2.4M	−$2.8M	−$2.0M
Diluted EPS	−$2.57	−$1.88	−$1.58	−$0.85	−$0.86	−$0.63
Gross margin	—	-661.9%	-1,607.1%	-1,282.5%	—	—
Operating margin	—	-44,147.1%	-98,637.8%	-85,713.2%	—	—

Fiscal years (4-quarter sums)FY22 $14.4K · FY23 $5.2K · FY24 $18.6K · FY25 $4.4K · FY26 $4.3K

Balance sheet, Apr 30, 2026Cash & short-term investments $1.66B · Total debt $3.9M · Total assets $5.3M · Shareholders' equity $226.1K

Dividends

No dividends on record.

Ownership

Institutions —Insiders 23.34%

Shares outstanding 2.16M · Float —

Float — provider float is below the insider stake.

The provider's float is smaller than the insider stake it should exclude, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Andrew Simpson · director, officer: See Remarks	499.4K	23.12%	Form 4	Jun 24, 2026
Digital Currency Group, Inc.	411.5K	9.40%	13D	Aug 18, 2026
Fields Ephraim G	265.2K	8.10%	13G	Jun 24, 2026
Mark T. Hilz · director, officer: COO, Secretary and Director	4.8K	0.22%	Form 4	Jul 30, 2025

Insider tradesForm 4

No open-market trades in the last 12 months.